Business UpdateApr 14, 2026, 06:02 AM
Greenwich LifeSciences reports $10.5M cash, 70-80% recurrence reduction
AI Summary
Greenwich LifeSciences provided an update on its financing strategy and Phase III FLAMINGO-01 clinical trial. The company's ATM financing raised more than its Q1 2026 cash burn, resulting in a cash balance of approximately $10.5 million as of March 31, 2026. Preliminary analysis of the fully enrolled 250-patient non-HLA-A*02 arm of the FLAMINGO-01 trial shows an approximately 70-80% reduction in breast cancer recurrence rates after the Primary Immunization Series, trending similarly to the Phase IIb results.
Key Highlights
- Q1 2026 cash balance approximately $10.5 million as of March 31, 2026.
- Phase III FLAMINGO-01 non-HLA-A*02 arm fully enrolled with 250 patients.
- Preliminary Phase III data shows 70-80% reduction in recurrence rate.
- Phase III screen rate is approximately 800 patients per year.
- Phase IIb trial showed 80% or greater recurrence reduction over 5 years.